Exchange: NASDAQ·Updated 04:42 PM EDT
ACOG logo

ACOG Alpha Cognition Inc

$9.26
$0.105
(1.13%)
Today
Closed $9.21
$0.0544
(0.59%)
After Hours
Reported EarningsAug 13
Mkt Cap$202.86M
Vol90,801.00

About ACOG

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.
34

Bearish Sentiment

How do you feel about ACOG?

Advertisement|Remove ads.